- Home
- RLYB vs NRXS Comparison
RLYB vs NRXS Comparison
Compare RLYB & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- NRXS
- Stock Information
- Founded
- RLYB 2018
- NRXS 2011
- Country
- RLYB United States
- NRXS United States
- Employees
- RLYB N/A
- NRXS N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- RLYB Health Care
- NRXS
- Exchange
- RLYB Nasdaq
- NRXS Nasdaq
- Market Cap
- RLYB 14.4M
- NRXS 13.0M
- IPO Year
- RLYB 2021
- NRXS 2023
- Fundamental
- Price
- RLYB $0.38
- NRXS $2.69
- Analyst Decision
- RLYB Hold
- NRXS
- Analyst Count
- RLYB 3
- NRXS 0
- Target Price
- RLYB $15.00
- NRXS N/A
- AVG Volume (30 Days)
- RLYB 163.1K
- NRXS 4.9M
- Earning Date
- RLYB 05-08-2025
- NRXS 05-12-2025
- Dividend Yield
- RLYB N/A
- NRXS N/A
- EPS Growth
- RLYB N/A
- NRXS N/A
- EPS
- RLYB N/A
- NRXS N/A
- Revenue
- RLYB $848,000.00
- NRXS $2,934,945.00
- Revenue This Year
- RLYB N/A
- NRXS $138,883.78
- Revenue Next Year
- RLYB N/A
- NRXS $118.59
- P/E Ratio
- RLYB N/A
- NRXS N/A
- Revenue Growth
- RLYB N/A
- NRXS 27.52
- 52 Week Low
- RLYB $0.22
- NRXS $1.33
- 52 Week High
- RLYB $1.73
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- RLYB 59.08
- NRXS 52.25
- Support Level
- RLYB $0.27
- NRXS $2.59
- Resistance Level
- RLYB $0.37
- NRXS $3.30
- Average True Range (ATR)
- RLYB 0.05
- NRXS 0.47
- MACD
- RLYB 0.01
- NRXS -0.03
- Stochastic Oscillator
- RLYB 81.54
- NRXS 15.01
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).